All In Biotech

Drug Trial Radar · NCT00176930

Stem Cell Transplant for Hematological Malignancy

Allogeneic Transplant for Hematological Malignancy

Last checked: Nov 19, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

330

Actual

Start

Oct 2001

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.

Conditions

  • Leukemia, Myeloid, Chronic
  • AML
  • Leukemia, Lymphocytic, Acute
  • MDS
  • Leukemia, Lymphocytic, Chronic
  • JMML
  • Hodgkin's Disease
  • Non-hodgkin's Lymphoma
  • Multiple Myeloma

Interventions

  • Stem Cell TransplantBiological

    Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)

  • CyclophosphamideDrug

    60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.

  • Total Body IrradiationRadiation

    On Day -4, -3, -2, -1 total body irradiation is given twice daily.

  • BusulfanDrug

    When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.

  • Equine ATG (ATGAM)Drug

    UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines

  • CD4+/CD25+ cellsBiological

    On days -2, patients will receive CD4+/CD25+ cells intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Disease-Free Survival at 2 Years Post TransplantTime frame: 2 years
  2. Number of Participants Experiencing Disease-Free Survival at 5 Years Post TransplantTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.